Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12427173

Use of bacteria, bacterial products, and other immunoregulatory entities in combination wi

Biomed Valley Discoveries, Inc. · Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414934

Combination therapies

Aardvark Therapeutics, Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12409167

Pharmaceutical combination comprising a selective S1P1 receptor agonist

VANDA PHARMACEUTICALS INC. · Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12404318

Combination HBV therapy

Vir Biotechnology, Inc. · Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12377101

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12377115

Combination immunotherapies for treatment of cancer

PrimeVax Immuno-Oncology · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12357586

Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epilepti

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12357650

Methods and compositions for cancer therapies that include delivery of halogenated thymidi

Shuttle Pharmaceuticals, Inc. · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12350318

Combination therapy to treat brain cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12338269

IL-2 superagonists in combination with anti-PD-1 antibodies

Medicenna Therapeutics Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12336995

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12318386

Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

Karyopharm Therapeutics Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12319738

Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

Five Prime Therapeutics, Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281173

Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in co

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280055

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12268694

Combination pharmaceutical agents as RSV inhibitors

Enanta Pharmaceuticals, Inc. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263173

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12258401

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12251397

Cross-linked hyaluronic acids and combinations with PRP/BMC

REGEN LAB SA · Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12246064

Method of treating Crohn's disease by administering a triple combination therapy of anti-i

Takeda Pharmaceutical Company Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12239712

Combination therapy for the treatment of liver disease

GALMED RESEARCH AND DEVELOPMENT LTD · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12233119

Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone

Prime Bio, Inc. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12233104

Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist

Nektar Therapeutics · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12220420

Combination therapy for cancer treatment

Galera Labs, LLC · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted